Wednesday, June 6, 2018, Baltimore, MD – Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the talk of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the Data Science in Africa Workshop, June 8, 2018 in Nyeri, Kenya.
Ogu’s talk “Converging Blockchain and next-generation Artificial Intelligence for biomedical research” will focus on the latest advances of AI in the biopharmaceutical industry and explore how AI is tending to transform local pharmaceutical companies in Africa. The presentation will also cover the recent applications of Blockchain technology for healthcare and drug discovery that can be utilized for local African problems in healthcare.
“The amount of medical data that are generated daily is immense, although people usually underestimate the value of their medical records, especially here, in Africa. These data could be used to develop excellent healthcar? products for many global and local African healthcare challenges. In Insilico we converge the advances in next-generation AI and Blockchain technologies to accelerate the development of such products”, said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant of Insilico Medicine, Inc.
“We are very happy to present our work at the Data Science in Africa Workshop, which brings together many African thought leaders in AI. The topic of AI and Blockchain for healthcare is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area”, said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
Data Science in Africa Workshop is the annual event that aims to train participants on machine learning and data science methods and demonstrate the application of these techniques to problems relevant in the African context. The workshop will unite data scientists, representatives from government, development practitioners and the private sector around African problems that could be solved using the advances in machine learning and artificial intelligence. The event will be held on June 7-8, 2018.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors’ Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:
Official Workshop Website:
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.
The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the “Bell Labs” for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video: https:/
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.